Post by joecoffee on Mar 24, 2014 8:23:23 GMT -5
Good Morning nice news out for TWSI $.5856
HemCon Medical Technologies, Inc. ("HemCon"), a wholly owned subsidiary of TriStar Wellness Solutions(R), Inc. (OTCQB: TWSI) and a leading developer and marketer of advanced medical products, announced today significant sales growth and momentum for the HemCon hemostatic product line in Japan. Sales for the first quarter of 2014 exceed overall sales for the previous year, and are trending to bring significant growth for the remainder of the year. This growth is fueled by new focus on sales and marketing efforts of HemCon's exclusive partner in Japan, Zeria Pharmaceuticals Ltd. Co. (Zeria), who has worked with the HemCon product line since 2010, ensuring the current and newly developed products become the standard of care for hemostasis in the country. Japan has the third largest global woundcare market, estimated to growth to $2.3B by 2016[1].
HemCon Medical Technologies, Inc. ("HemCon"), a wholly owned subsidiary of TriStar Wellness Solutions(R), Inc. (OTCQB: TWSI) and a leading developer and marketer of advanced medical products, announced today significant sales growth and momentum for the HemCon hemostatic product line in Japan. Sales for the first quarter of 2014 exceed overall sales for the previous year, and are trending to bring significant growth for the remainder of the year. This growth is fueled by new focus on sales and marketing efforts of HemCon's exclusive partner in Japan, Zeria Pharmaceuticals Ltd. Co. (Zeria), who has worked with the HemCon product line since 2010, ensuring the current and newly developed products become the standard of care for hemostasis in the country. Japan has the third largest global woundcare market, estimated to growth to $2.3B by 2016[1].